Recently, a third generation EGFR-TKI (Osimertinib) has been approved by the US FDA to treat patients with a type of advanced NSCLC that has a specific EGFR mutation, called T790M, and which has become worse after treatment with other EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.